Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
Latest News
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
Is Intestinal Dysbiosis Associated with RA?
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.
What the Joints Say: Challenges of Tender & Swollen Joint Count Differences
In a new study published in ACR Open Rheumatology, researchers evaluated the impact of tender-swollen joint difference on functional outcomes in early RA and whether associations vary by joint size.
Interventions to Delay RA Onset
Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
ACR Convergence Sessions on AI, APPs Can Boost Practice Efficiency
Sessions on the use of AI to aid documentation and on hiring advanced practice providers could help your rheumatology practice save time and money.
Rheum for Everyone, Episode 13: Dr. Jekyll or Mr. Hyde? (video)
In this video, Dr. Bharat Kumar talks about the seven virtues of rheumatology practice that clinicians should embrace and what deadly sins to avoid.
A Practical Guide to Autoantibody Testing in Rheumatic Diseases
“ANA’s are some of most commonly ordered tests but what exactly are they and what do you do with a positive ANA? Check out the Editor’s Pick for October to learn more,” says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS.
The 7 Virtues of Rheumatology We Should Cultivate
1949 was a momentous year—astronomer Fred Hoyle coined the term Big Bang, the North Atlantic Treaty Organization (NATO) was formed, and Rodgers and Hammerstein’s classic…